“As the coronavirus mushroomed across the rest of the world, a global shortage of N95s would develop and test 3M like nothing else in its 118-year history.”
“Entering the year, only 15% of 3M’s N95s were made for health care customers. Not even four months later, it’s now 90%. That “flip” was done at the same time 3M raced to quadruple production rates, said Denise Rutherford, 3M’s senior vice president for corporate affairs.”
“The dash to ramp up production involved opening idled production lines and finding factory workers to get them going. It meant overcoming regulatory and trade barriers, changing supply chains on the fly and reconfiguring its distribution.”
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.